Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 4
2010 2
2011 1
2014 2
2015 1
2016 4
2017 2
2018 5
2019 3
2020 3
2021 6
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
Kohlmeyer JL, Lingo JJ, Kaemmer CA, Scherer A, Warrier A, Voigt E, Raygoza Garay JA, McGivney GR, Brockman QR, Tang A, Calizo A, Pollard K, Zhang X, Hirbe AC, Pratilas CA, Leidinger M, Breheny P, Chimenti MS, Sieren JC, Monga V, Tanas MR, Meyerholz DK, Darbro BW, Dodd RD, Quelle DE. Kohlmeyer JL, et al. Among authors: tanas mr. Clin Cancer Res. 2023 Sep 1;29(17):3484-3497. doi: 10.1158/1078-0432.CCR-23-0749. Clin Cancer Res. 2023. PMID: 37410426 Free PMC article.
PRC2 loss drives MPNST metastasis and matrix remodeling.
Brockman QR, Scherer A, McGivney GR, Gutierrez WR, Voigt AP, Isaacson AL, Laverty EA, Roughton G, Knepper-Adrian V, Darbro B, Tanas MR, Stipp CS, Dodd RD. Brockman QR, et al. Among authors: tanas mr. JCI Insight. 2022 Oct 24;7(20):e157502. doi: 10.1172/jci.insight.157502. JCI Insight. 2022. PMID: 36066973 Free PMC article.
Combination therapies for MPNSTs targeting RABL6A-RB1 signaling.
Kohlmeyer JL, Gordon DJ, Tanas MR, Dodd RD, Monga V, Darbro BW, Quelle DE. Kohlmeyer JL, et al. Among authors: tanas mr. Oncotarget. 2021 Jan 5;12(1):10-14. doi: 10.18632/oncotarget.27862. eCollection 2021 Jan 5. Oncotarget. 2021. PMID: 33456709 Free PMC article.
Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.
Kohlmeyer JL, Kaemmer CA, Lingo JJ, Voigt E, Leidinger MR, McGivney GR, Scherer A, Koppenhafer SL, Gordon DJ, Breheny P, Meyerholz DK, Tanas MR, Dodd RD, Quelle DE. Kohlmeyer JL, et al. Among authors: tanas mr. Neurooncol Adv. 2022 Apr 9;4(1):vdac047. doi: 10.1093/noajnl/vdac047. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35571990 Free PMC article.
Cutaneous Metastasis of Alveolar Rhabdomyosarcoma in a Child.
Nör F, Castro JP, Wongpattaraworakul W, Buatti JM, Gordon D, Powers JG, Terry W, Hellstein J, Tanas M, Stone M. Nör F, et al. Among authors: tanas m. Am J Dermatopathol. 2023 Mar 1;45(3):e17-e21. doi: 10.1097/DAD.0000000000002382. Epub 2023 Jan 10. Am J Dermatopathol. 2023. PMID: 36728280
Abl kinases can function as suppressors of tumor progression and metastasis.
Marchal MA, Moose DL, Varzavand A, Jordan NE, Taylor D, Tanas MR, Brown JA, Henry MD, Stipp CS. Marchal MA, et al. Among authors: tanas mr. Front Oncol. 2023 Sep 8;13:1241056. doi: 10.3389/fonc.2023.1241056. eCollection 2023. Front Oncol. 2023. PMID: 37746268 Free PMC article.
A comprehensive evaluation of Hippo pathway silencing in sarcomas.
Merritt NM, Fullenkamp CA, Hall SL, Qian Q, Desai C, Thomason J, Lambertz AM, Dupuy AJ, Darbro B, Tanas MR. Merritt NM, et al. Among authors: tanas mr. Oncotarget. 2018 Aug 3;9(60):31620-31636. doi: 10.18632/oncotarget.25824. eCollection 2018 Aug 3. Oncotarget. 2018. PMID: 30167083 Free PMC article.
39 results